Tuesday, June 9, 2020
AstraZeneca is planning to start a phase 1 clinical trial of a COVID-19 antibody therapy within two months. The commitment follows the signing of a deal that grants AstraZeneca an exclusive license to six anti-SARS-CoV-2 antibodies identified by researchers at Vanderbilt University.
read more
Tuesday, June 9, 2020
Biopharma M&A has seen a sharp decline so far this year, both in terms of monetary value and total transaction count, amid a COVID-19 business slowdown. But executives from Johnson & Johnson, Takeda and Horizon Therapeutics said their companies' M&A strategies remain unchanged.
read more
Tuesday, June 9, 2020
The COVID-19 pandemic has thrown a curve ball at the global economy, and the biopharma industry is no exception. Companies are scrambling to develop tests, treatments and vaccines for the disease, while making sure not to neglect their pipelines. We caught up with Ioannis Sapountzis, Boehringer Ingelheim’s global head of business development and licensing, to see how the German pharma is handling this.
read more
Tuesday, June 9, 2020
AstraZeneca has "lost interest" in a potentially record-setting merger with Gilead, The Times of London reported. GlaxoSmithKline will test its arthritis antibody otilimab in severely-ill COVID patients. Plus, Fujifilm plans to invest nearly $1 billion in a former Biogen plant, and a WHO expert walked back claims about how the virus spreads.
read more
Tuesday, June 9, 2020
Follow along with the latest COVID-19 news straight from the FierceHealthcare team.
read more
Tuesday, June 9, 2020
Amid reports that the company plans to go public, Amwell CEOs Roy and Ido Schoenberg talk to FierceHealthcare about the future of telehealth. Find out why the executives believe the surge in virtual visits represents "nothing short of a revolution" in healthcare.
read more
Tuesday, June 9, 2020
Anthem is reaffirming its 2020 guidance and will be reaching out to investors over the next several weeks, according to financial documents.
read more
